Velcade - $692.7 million

Image courtesy of Wikipedia

Velcade

Company:
Millennium Pharmaceuticals, a unit of Takeda Pharmaceutical Industries, in partnership with Johnson & Johnson
2011 sales: $692.7 million
Developer: Millennium Pharmaceuticals
FDA approvals: Multiple myeloma, 2003; mantle cell lymphoma, 2006; first-line multiple myeloma, 2008

If not for Velcade, Millennium Pharmaceuticals probably wouldn't be part of Japan's Takeda Pharmaceutical Industries right now. The Japanese company paid $8.8 billion for Millennium in 2008 as part of its bid to replace sales of Actos and Prevacid, blockbuster treatments that now face generic rivals. And Velcade was pegged as a potential blockbuster at the time--a milestone it achieved later that year.

In the U.S., sales continue to grow at double-digit rates. 2010 sales of $580 million beat 2009 by a 21% margin, and 2011 marked another 19% growth. And that could accelerate significantly this year, now that the drug has an entirely new FDA approval.

The agency gave its blessing to subcutaneous administration of Velcade in January; the drug previously was administered intravenously. Not only was the under-the-skin injection easier, it also proved to reduce side effects in a Phase III trial. Patients who couldn't tolerate Velcade before may be able to now. As Millennium CEO Deborah Dunsire said at the time, "That could be a reason for sales to expand." We'll check back in next year.

Velcade - $692.7 million
Read more on

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.